FI105153B - Menetelmä farmaseuttisten, suun kautta annettavien dideoksipuriininukleosidikoostumusten valmistamiseksi - Google Patents
Menetelmä farmaseuttisten, suun kautta annettavien dideoksipuriininukleosidikoostumusten valmistamiseksi Download PDFInfo
- Publication number
- FI105153B FI105153B FI923308A FI923308A FI105153B FI 105153 B FI105153 B FI 105153B FI 923308 A FI923308 A FI 923308A FI 923308 A FI923308 A FI 923308A FI 105153 B FI105153 B FI 105153B
- Authority
- FI
- Finland
- Prior art keywords
- magnesium
- tablet
- insoluble
- antacid
- water
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 238000000034 method Methods 0.000 title claims description 25
- 230000008569 process Effects 0.000 title claims description 13
- 239000002777 nucleoside Substances 0.000 title claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 57
- 238000009472 formulation Methods 0.000 claims abstract description 56
- 239000003159 antacid agent Substances 0.000 claims abstract description 37
- 239000003826 tablet Substances 0.000 claims abstract description 37
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 15
- 239000011777 magnesium Substances 0.000 claims abstract description 15
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 15
- SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 claims abstract description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940069428 antacid Drugs 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 33
- 230000001458 anti-acid effect Effects 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- -1 magnesium antacid compound Chemical class 0.000 claims description 17
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 15
- 108010011485 Aspartame Proteins 0.000 claims description 14
- 239000000605 aspartame Substances 0.000 claims description 14
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 14
- 229960003438 aspartame Drugs 0.000 claims description 14
- 235000010357 aspartame Nutrition 0.000 claims description 14
- 239000004615 ingredient Substances 0.000 claims description 14
- 239000000347 magnesium hydroxide Substances 0.000 claims description 14
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 239000006185 dispersion Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 6
- 229940096978 oral tablet Drugs 0.000 claims description 6
- 239000007935 oral tablet Substances 0.000 claims description 6
- 239000007968 orange flavor Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 4
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 4
- 239000004137 magnesium phosphate Substances 0.000 claims description 4
- 229960002261 magnesium phosphate Drugs 0.000 claims description 4
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 4
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 4
- 229940042126 oral powder Drugs 0.000 claims description 4
- 241001672694 Citrus reticulata Species 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- HDVDLQFPDLTOSI-UHFFFAOYSA-L O[AlH]O Chemical compound O[AlH]O HDVDLQFPDLTOSI-UHFFFAOYSA-L 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- UOVKYUCEFPSRIJ-UHFFFAOYSA-D hexamagnesium;tetracarbonate;dihydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O UOVKYUCEFPSRIJ-UHFFFAOYSA-D 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 31
- 229940079593 drug Drugs 0.000 abstract description 30
- 239000000843 powder Substances 0.000 abstract description 16
- 239000007910 chewable tablet Substances 0.000 abstract description 14
- 239000007919 dispersible tablet Substances 0.000 abstract description 8
- 229940015828 dihydroxyaluminum sodium carbonate Drugs 0.000 abstract description 4
- 230000003139 buffering effect Effects 0.000 abstract 2
- 150000003834 purine nucleoside derivatives Chemical class 0.000 abstract 1
- 229960002656 didanosine Drugs 0.000 description 29
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 27
- 239000002253 acid Substances 0.000 description 16
- 235000010216 calcium carbonate Nutrition 0.000 description 11
- 239000008363 phosphate buffer Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 10
- 239000007979 citrate buffer Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 239000013256 coordination polymer Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 4
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940068682 chewable tablet Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000005223 Alkalosis Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- TUOFDTDURRKFTE-UHFFFAOYSA-J [K+].O[Al+]O.[O-]C([O-])=O Chemical compound [K+].O[Al+]O.[O-]C([O-])=O TUOFDTDURRKFTE-UHFFFAOYSA-J 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000002340 alkalosis Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940031395 didanosine chewable tablet Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001676573 Minium Species 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- PPQREHKVAOVYBT-UHFFFAOYSA-H aluminium carbonate Inorganic materials [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 description 1
- UDYRPJABTMRVCX-UHFFFAOYSA-J dimagnesium;carbonate;dihydroxide Chemical compound [OH-].[OH-].[Mg+2].[Mg+2].[O-]C([O-])=O UDYRPJABTMRVCX-UHFFFAOYSA-J 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000012065 two one-sided test Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73354791A | 1991-07-22 | 1991-07-22 | |
| US73354791 | 1991-07-22 | ||
| US88220492A | 1992-05-13 | 1992-05-13 | |
| US88220492 | 1992-05-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI923308A0 FI923308A0 (fi) | 1992-07-20 |
| FI923308L FI923308L (fi) | 1993-01-23 |
| FI105153B true FI105153B (fi) | 2000-06-30 |
Family
ID=27112590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI923308A FI105153B (fi) | 1991-07-22 | 1992-07-20 | Menetelmä farmaseuttisten, suun kautta annettavien dideoksipuriininukleosidikoostumusten valmistamiseksi |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5880106A (enExample) |
| EP (1) | EP0524579B1 (enExample) |
| JP (1) | JP3038456B2 (enExample) |
| KR (1) | KR960011772B1 (enExample) |
| CN (1) | CN1042299C (enExample) |
| AT (1) | ATE163855T1 (enExample) |
| AU (1) | AU657337B2 (enExample) |
| CA (1) | CA2074215C (enExample) |
| DE (1) | DE69224684T2 (enExample) |
| DK (1) | DK0524579T3 (enExample) |
| ES (1) | ES2113389T3 (enExample) |
| FI (1) | FI105153B (enExample) |
| GR (1) | GR3026332T3 (enExample) |
| HU (3) | HU9202318D0 (enExample) |
| IE (1) | IE922365A1 (enExample) |
| IL (1) | IL102519A (enExample) |
| MX (1) | MX9204256A (enExample) |
| NO (1) | NO300198B1 (enExample) |
| NZ (1) | NZ243567A (enExample) |
| PL (1) | PL295329A1 (enExample) |
| RU (1) | RU2089193C1 (enExample) |
| TW (1) | TW211521B (enExample) |
| ZA (1) | ZA925484B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| CN1325305A (zh) * | 1998-06-18 | 2001-12-05 | 乔治华盛顿大学 | 以低的副作用施用喜树碱化合物治疗癌症的方法 |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| US20040028772A1 (en) * | 2000-08-14 | 2004-02-12 | Carsten Andersen | Method for preparation of chewing gum with customer acceptable taste |
| US6887926B1 (en) | 2001-11-16 | 2005-05-03 | Oatey Co. | Bonding compositions for chlorinated polymers and methods of using the same |
| CN100415211C (zh) * | 2003-07-03 | 2008-09-03 | 上海现代药物制剂工程研究中心 | 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法 |
| RU2276992C2 (ru) * | 2004-07-12 | 2006-05-27 | Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) | Фармацевтический состав, обладающий ноотропной активностью |
| US20080299227A1 (en) * | 2007-05-30 | 2008-12-04 | Sunhealth Therapies, Inc. | Method for removal of HIV from the gastrointestinal tract and bile of HIV-infected subjects and for the prevention of drug failure and prevention of development of AIDS in HIV-infected subjects |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| BRPI0923815A2 (pt) | 2008-12-23 | 2015-07-14 | Pharmasset Inc | Síntese de nucleosídeos de purina |
| EA019341B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Фосфорамидаты нуклеозидов |
| EP2376514A2 (en) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| LT2609923T (lt) | 2010-03-31 | 2017-09-11 | Gilead Pharmasset Llc | (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
| CN102949406B (zh) * | 2011-08-31 | 2014-03-12 | 天津药物研究院 | 一种复方艾夫他滨药物组合物及其制备方法和用途 |
| AR089857A1 (es) * | 2012-02-02 | 2014-09-24 | Glaxosmithkline Llc | Comprimido antiacido para refrescar el aliento |
| US10835495B2 (en) | 2012-11-14 | 2020-11-17 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same |
| CN104069126A (zh) * | 2014-07-02 | 2014-10-01 | 浙江康乐药业股份有限公司 | 一种治疗胃酸过多的药物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260596A (en) * | 1979-08-13 | 1981-04-07 | Bristol-Myers Company | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same |
| US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
| CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
| WO1987001284A1 (en) * | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US4921707A (en) * | 1986-06-24 | 1990-05-01 | Istvan Racz | Proceeding for the production of pharmaceutical preparations of high gastric acid binding capacity, of retarded effect and of increased bioavailability |
| WO1988002629A1 (en) * | 1986-10-16 | 1988-04-21 | American Health Products Corporation | 2',3'-didesoxyadenosine composition |
| US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
-
1992
- 1992-07-15 NZ NZ243567A patent/NZ243567A/en unknown
- 1992-07-15 HU HU9202318A patent/HU9202318D0/hu unknown
- 1992-07-16 NO NO922807A patent/NO300198B1/no not_active IP Right Cessation
- 1992-07-16 TW TW081105639A patent/TW211521B/zh not_active IP Right Cessation
- 1992-07-16 JP JP4231248A patent/JP3038456B2/ja not_active Expired - Lifetime
- 1992-07-16 IL IL10251992A patent/IL102519A/en not_active IP Right Cessation
- 1992-07-17 PL PL29532992A patent/PL295329A1/xx unknown
- 1992-07-20 CA CA002074215A patent/CA2074215C/en not_active Expired - Fee Related
- 1992-07-20 AT AT92112371T patent/ATE163855T1/de active
- 1992-07-20 DE DE69224684T patent/DE69224684T2/de not_active Expired - Lifetime
- 1992-07-20 FI FI923308A patent/FI105153B/fi not_active IP Right Cessation
- 1992-07-20 EP EP92112371A patent/EP0524579B1/en not_active Expired - Lifetime
- 1992-07-20 AU AU20396/92A patent/AU657337B2/en not_active Expired
- 1992-07-20 DK DK92112371.7T patent/DK0524579T3/da active
- 1992-07-20 ES ES92112371T patent/ES2113389T3/es not_active Expired - Lifetime
- 1992-07-21 ZA ZA925484A patent/ZA925484B/xx unknown
- 1992-07-21 MX MX9204256A patent/MX9204256A/es unknown
- 1992-07-21 IE IE236592A patent/IE922365A1/en not_active IP Right Cessation
- 1992-07-21 RU SU925052174A patent/RU2089193C1/ru active
- 1992-07-21 CN CN92108657A patent/CN1042299C/zh not_active Expired - Lifetime
- 1992-07-21 KR KR1019920012989A patent/KR960011772B1/ko not_active Expired - Lifetime
- 1992-07-21 HU HU9202375A patent/HU220612B1/hu unknown
-
1995
- 1995-06-20 HU HU95P/P00275P patent/HU211285A9/hu unknown
-
1997
- 1997-10-02 US US08/942,660 patent/US5880106A/en not_active Expired - Lifetime
-
1998
- 1998-03-12 GR GR970402511T patent/GR3026332T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI105153B (fi) | Menetelmä farmaseuttisten, suun kautta annettavien dideoksipuriininukleosidikoostumusten valmistamiseksi | |
| FI77371C (fi) | Foerfarande foer framstaellning av en kapsel, som innehaoller ett alkaliskt aemne och acetylsalicylsyra. | |
| ES2301537T3 (es) | Comprimidos y formulacion de guaifenesina de liberacion sostenida. | |
| US6656505B2 (en) | Method for forming an aqueous flocculated suspension | |
| JP2008231120A (ja) | アジスロマイシン投与法 | |
| JP2003519656A (ja) | 新規な置換ベンズイミダゾール投与形態およびそれらの使用方法 | |
| EP2402003A2 (en) | Diclofenac formulations and methods of use | |
| CZ345997A3 (cs) | Použití trihydrátu amoxycilinu a klavulanátu draselného, faramceutický prostředek obsahující tyto složky a způsob přípravy tohoto prostředku | |
| CN108904808A (zh) | 一种治疗便秘的药物组合物及其应用 | |
| JPH03206046A (ja) | 腸管洗浄液用組成物及び腸管洗浄液 | |
| US6793935B2 (en) | Mineral supplement | |
| JPH05506238A (ja) | 薬学的処方物 | |
| CN1964699A (zh) | 干燥形态经口摄取用组合物和用时调制型凝胶状经口摄取用组合物 | |
| Ekenved et al. | In vivo studies on the neutralizing effect of antacids using the Heidelberg capsule | |
| KR100367877B1 (ko) | 구연산칼륨을 주제로 한 요로결석 치료제중 분말 및 미립제형 의 제조방법 | |
| CZ79593A3 (en) | Antitussive preparation | |
| WO2009092002A1 (en) | Antiretroviral drug formulations for treatment of children exposed to hiv/aids | |
| EP0051207B1 (en) | A pharmaceutical mixture containing sodium cromoglycate and a method of making the mixture | |
| JPH11322606A (ja) | 易嚥下性抗悪性腫瘍製剤 | |
| GB2086227A (en) | Sodium cromoglycate reconstitutable powders | |
| JPH11116495A (ja) | 服用感の改善されたビタミン配合薬 | |
| EP1894557A1 (en) | Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore | |
| EA042006B1 (ru) | Композиция в качестве добавки кальция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |